XML 56 R41.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Assignment, License and Collaboration Agreements - Additional Information (Details) ¥ in Millions |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Nov. 30, 2021 USD ($) | Jul. 31, 2022 USD ($) | Jul. 31, 2020 USD ($) | Jun. 30, 2019 CNY (¥) | Mar. 31, 2018 USD ($) | Feb. 28, 2018 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Jun. 30, 2022 | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($)
TERN-101 License Agreement with Eli Lilly |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement milestones payment |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |
Research and development expense |  |  |  |  |  |  | $ 0 | $ 0 |  | 0 | $ 0 |  |  |
TERN-101 License Agreement with Eli Lilly | China |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate pre-specified development milestones for the first covered product |  |  |  |  |  | $ 6,000,000.0 |  |  |  |  |  |  |  |
Aggregate pre-specified development milestones for the first covered product in ex-mainland |  |  |  |  |  | $ 50,000,000.0 |  |  |  |  |  |  |  |
TERN-201 License Agreement with Eli Lilly |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate pre-specified development milestones for the first covered product in ex-mainland |  |  |  |  | $ 74,000,000.0 |  |  |  |  |  |  |  |  |
Agreement milestones payment |  |  |  |  |  |  |  |  |  | 0 |  |  |  |
Research and development expense |  |  |  |  |  |  | 0 | 0 |  | 0 | $ 0 |  |  |
Aggregate pre-specified development milestones for second indication of covered product |  |  |  |  | $ 30,000,000.0 |  |  |  |  |  |  |  |  |
Amount paid under the agreement |  |  |  |  |  |  |  |  |  | 4,000,000.0 |  |  |  |
TERN-201 License Agreement with Eli Lilly | Research and Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000,000.0
Assignment Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate pre-specified development milestones for the first covered product | ¥ |  |  |  | ¥ 205.0 |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  | 0 | $ 0 |  | 0 |  |  |  |
Amount paid under the agreement |  |  |  |  |  |  |  |  |  | 4,400,000 |  |  |  |
Number of days advance written notice |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  |  | 1,500,000 |  |  |  |
Assignment Agreement | Research and Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 700,000 |
Hansoh Option and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  |  |  | $ 800,000 |  |
License revenue | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Hansoh Option and License Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount agree to pay in pre-specified clinical, regulatory and sales milestones |  |  | $ 67,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Phase 2a DUET |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  | $ 2,200,000 |  |  | $ 2,200,000 |  |  |  |
Milestone payment |  | $ 2,200,000 |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Aggregate pre specified development milestones for second indication product. + References No definition available. + Details
Name: | tern_AggregatePreSpecifiedDevelopmentMilestonesForSecondIndicationProduct
Namespace Prefix: | tern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate pre specified development milestones product ex mainland. + References No definition available. + Details
Name: | tern_AggregatePreSpecifiedDevelopmentMilestonesProductExMainland
Namespace Prefix: | tern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate pre specified development milestones product mainland. + References No definition available. + Details
Name: | tern_AggregatePreSpecifiedDevelopmentMilestonesProductMainland
Namespace Prefix: | tern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Agreement milestones payment. + References No definition available. + Details
Name: | tern_AgreementMilestonesPayment
Namespace Prefix: | tern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Assignment license and collaboration agreements. + References No definition available. + Details
Name: | tern_AssignmentLicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | tern_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | tern_MilestonePayment
Namespace Prefix: | tern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of days advance written notice. + References No definition available. + Details
Name: | tern_NumberOfDaysAdvanceWrittenNotice
Namespace Prefix: | tern_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option and license agreement pre specified clinical regulatory sales milestones. + References No definition available. + Details
Name: | tern_OptionAndLicenseAgreementPreSpecifiedClinicalRegulatorySalesMilestones
Namespace Prefix: | tern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | tern_UpfrontPayment
Namespace Prefix: | tern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | tern_UpfrontPaymentReceived
Namespace Prefix: | tern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment research and development expense. + References No definition available. + Details
Name: | tern_UpfrontPaymentResearchAndDevelopmentExpense
Namespace Prefix: | tern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tern_TERNOneHundredAndOneLicenseAgreementWithEliLillyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tern_TERNTwoHundredAndOneLicenseAgreementWithEliLillyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tern_AssignmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tern_HansohOptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tern_Phase2ADuetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |